Generation of monoclonal antibodies to the anti-trypanosomal drug isometamidium.
Mice were immunized with either an isometamidium-human serum albumin (HSA) conjugate or an isometamidium-porcine thyroglobulin conjugate (PTG). Thereafter, monoclonal antibodies (MAbs) IL-A 1001, IL-A 1002, IL-A 1003, 5F7.B7, and 5F7.C9 were generated and selected on the basis that they recognized conjugated and unconjugated isometamidium, but lacked cross-reactivity with the carrier molecules. All five MAbs were of the IgG1 isotype. Each of the five MAbs was assessed in a competitive ELISA for isometamidium; in each case, the minimum level of detection was approximately 10 ng/ml. Each MAb exhibited approximately 0.1% cross-reactivity with the anti-trypanosomal compound diminazene. However, based on their cross-reactivity with the anti-trypanosomal compound homidium, the MAbs could be divided into two groups; IL-A 1001, IL-A 1002, and IL-A 1003, produced using an isometamidium-HSA conjugate as an immunogen, exhibited low levels of cross-reactivity (approximately 0.1%). In contrast, 5F7.B7 and 5F7.C9, produced using an isometamidium-PTG conjugate as an immunogen, exhibited high levels of cross-reactivity.
Peregrine
A S
AS
International Laboratory for Research on Animal Diseases (ILRAD), Nairobi, Kenya.
Eisler
M C
MC
Katende
J
J
Flynn
J N
JN
Gault
E A
EA
Kinabo
L D
LD
Holmes
P H
PH
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000918:Antibody Specificity; D004133:Diminazene / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D004996:Ethidium / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D010617:Phenanthridines / Q000276:immunology*; D014344:Trypanocidal Agents / Q000276:immunology*
D000911:Antibodies, Monoclonal; D010617:Phenanthridines; D014344:Trypanocidal Agents; C000702:isometamidium chloride; D004996:Ethidium; D004133:Diminazene